CR20140277A - DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME - Google Patents
DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAMEInfo
- Publication number
- CR20140277A CR20140277A CR20140277A CR20140277A CR20140277A CR 20140277 A CR20140277 A CR 20140277A CR 20140277 A CR20140277 A CR 20140277A CR 20140277 A CR20140277 A CR 20140277A CR 20140277 A CR20140277 A CR 20140277A
- Authority
- CR
- Costa Rica
- Prior art keywords
- derivatives
- methods
- compounds
- azaadamantano
- same
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- WENISBCJPGSITQ-UHFFFAOYSA-N 1-azatricyclo[3.3.1.13,7]decane Chemical class C1C(C2)CC3CC1CN2C3 WENISBCJPGSITQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001412 amines Chemical group 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001033 ether group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000651 prodrug Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Compuestos que son derivados de azaadamantano, particularmente derivados de azaadamantano sustituidos con éter o amina, y sales y prodrogas de éstos, composiciones que comprenden estos compuestos, métodos para usar estos compuestos y composiciones, procesos para preparar estos compuestos, e intermediarios obtenidos durante estos procesos.Compounds that are derivatives of azaadamantane, particularly azaadamantane derivatives substituted with ether or amine, and salts and prodrugs thereof, compositions comprising these compounds, methods for using these compounds and compositions, processes for preparing these compounds, and intermediates obtained during these processes .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85699206P | 2006-11-06 | 2006-11-06 | |
US90814307P | 2007-03-26 | 2007-03-26 | |
US11/935,257 US20080122023A1 (en) | 2006-11-29 | 2007-11-05 | Method of manufacturing cmos image sensor |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140277A true CR20140277A (en) | 2014-09-23 |
Family
ID=39594848
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10743A CR10743A (en) | 2006-11-06 | 2009-04-23 | DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME |
CR20140277A CR20140277A (en) | 2006-11-06 | 2014-06-13 | DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10743A CR10743A (en) | 2006-11-06 | 2009-04-23 | DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME |
Country Status (29)
Country | Link |
---|---|
US (3) | US8314119B2 (en) |
EP (1) | EP2099795B1 (en) |
JP (4) | JP5275246B2 (en) |
KR (4) | KR20140116558A (en) |
CN (1) | CN103554107B (en) |
AU (1) | AU2007316480B2 (en) |
BR (1) | BRPI0718028A2 (en) |
CA (1) | CA2668962C (en) |
CO (1) | CO6210720A2 (en) |
CR (2) | CR10743A (en) |
DK (1) | DK2099795T3 (en) |
DO (3) | DOP2011000301A (en) |
EC (1) | ECSP099388A (en) |
ES (1) | ES2551117T3 (en) |
HK (1) | HK1133645A1 (en) |
IL (2) | IL198587A (en) |
MX (2) | MX2009004813A (en) |
MY (1) | MY148253A (en) |
NO (1) | NO20092181L (en) |
NZ (4) | NZ577474A (en) |
PH (1) | PH12013500745A1 (en) |
PL (1) | PL2099795T3 (en) |
PT (1) | PT2099795E (en) |
RU (2) | RU2450002C2 (en) |
SG (1) | SG176473A1 (en) |
TW (1) | TWI511729B (en) |
UA (1) | UA96961C2 (en) |
WO (1) | WO2008058096A2 (en) |
ZA (3) | ZA200903944B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR049401A1 (en) * | 2004-06-18 | 2006-07-26 | Novartis Ag | AZA-BICICLONONANS |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
JP5539216B2 (en) * | 2007-11-20 | 2014-07-02 | メルク・シャープ・アンド・ドーム・コーポレーション | Non-nucleoside reverse transcriptase inhibitors |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
JP2012530084A (en) * | 2009-06-19 | 2012-11-29 | アボット・ラボラトリーズ | Diazahomoadamantane derivatives and methods of use thereof |
GB0912946D0 (en) | 2009-07-24 | 2009-09-02 | Addex Pharmaceuticals Sa | New compounds 5 |
TWI558398B (en) | 2009-09-22 | 2016-11-21 | 諾華公司 | Use of nicotinic acetylcholine receptor alpha 7 activators |
BR112013005084A2 (en) * | 2010-09-02 | 2020-08-25 | Suven Life Sciences Limited | compound, pharmaceutical composition, process for preparing a compound and method of treating disorders |
MX2013003344A (en) * | 2010-09-23 | 2013-06-28 | Abbvie Inc | Monohydrate of an azaadamantane derivative. |
CA2825142A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
US8802693B1 (en) * | 2011-03-09 | 2014-08-12 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
EA201391348A8 (en) | 2011-03-18 | 2014-11-28 | Новартис Аг | COMBINATION OF ALPHA-7 ACTIVATORS OF NICOTINE ACETYL-CHOLINE RECEPTOR AND ANTAGONISTS mGluR5, INTENDED FOR APPLICATION FOR DOPKINOM-CAUSED DYSKINESIA, ASSOCIATED WITH CAROSTERN DISEASE |
JP2014510105A (en) | 2011-03-22 | 2014-04-24 | アムジエン・インコーポレーテツド | Azole compounds as PIM inhibitors |
EA034964B1 (en) | 2011-10-20 | 2020-04-13 | Новартис Аг | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
US20130317056A1 (en) * | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonists and methods of correlating comt snps |
US20130317054A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
US20130317055A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
KR102043309B1 (en) | 2012-12-11 | 2019-11-11 | 노파르티스 아게 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
EP2945633B1 (en) | 2013-01-15 | 2021-06-30 | Novartis AG | Use of alpha 7 nicotinic acetylcholine receptor agonists |
WO2014111751A1 (en) | 2013-01-15 | 2014-07-24 | Novartis Ag | Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy |
JP2016508159A (en) | 2013-01-15 | 2016-03-17 | ノバルティス アーゲー | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US8969562B2 (en) * | 2013-03-12 | 2015-03-03 | Abbvie, Inc. | Azaadamantane formate ester and process for preparing azaadamantane derivatives |
US10183938B2 (en) | 2014-12-16 | 2019-01-22 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors |
MX2017016231A (en) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors. |
US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
CN110946865B (en) | 2015-12-10 | 2024-01-26 | Ptc医疗公司 | Methods for treating huntington's disease |
BR112019025740A2 (en) | 2017-06-05 | 2020-06-23 | Ptc Therapeutics, Inc. | COMPOUNDS TO TREAT HUNTINGTON'S DISEASE |
BR112019027719A2 (en) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | methods to treat huntington's disease |
US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
EP3689863A1 (en) | 2017-08-04 | 2020-08-05 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
JP6638716B2 (en) * | 2017-11-20 | 2020-01-29 | コベルコ建機株式会社 | Construction machine car body |
SG11202009212WA (en) | 2018-03-27 | 2020-10-29 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
EA202092896A1 (en) | 2018-06-27 | 2021-04-13 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
CN109232474B (en) * | 2018-09-27 | 2021-08-06 | 武汉尚赛光电科技有限公司 | 1,2, 4-thiadiazole compound and preparation method and application thereof |
WO2020163323A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
KR20210135507A (en) | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | Methods and compositions for controlling splicing |
WO2020172609A1 (en) * | 2019-02-21 | 2020-08-27 | Marquette University | Heterocyclic ligands of par1 and methods of use |
US11130743B2 (en) | 2019-02-21 | 2021-09-28 | Marquette University | Heterocyclic ligands of PAR1 and methods of use |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2514006A1 (en) | 1981-10-05 | 1983-04-08 | Nativelle Sa Ets | ACYLAMINO-4 AZA-1 ADAMANTANES, PROCESS FOR THEIR PREPARATION, AND THERAPEUTIC APPLICATION |
EP0088484A1 (en) | 1982-02-04 | 1983-09-14 | Fbc Limited | Herbicidal thiadiazolyl N-aminoureas |
GB8523211D0 (en) | 1985-09-19 | 1985-10-23 | Beecham Group Plc | Compounds |
EP0350130A3 (en) * | 1988-07-07 | 1991-07-10 | Duphar International Research B.V | New substituted 1,7-annelated 1h-indazoles |
US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5385912A (en) * | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
WO1992015579A1 (en) | 1991-03-08 | 1992-09-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
US5280028A (en) | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
US5434151A (en) * | 1992-08-24 | 1995-07-18 | Cytomed, Inc. | Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase |
US5840903A (en) * | 1992-07-27 | 1998-11-24 | G. D. Searle & Co. | 4-aminomethyl-1-azaadamantane derived benzamides |
JP3235913B2 (en) | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | Aminobenzoic acid derivative |
US5399562A (en) * | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
US5821371A (en) | 1994-10-24 | 1998-10-13 | Eli Lilly And Comany | Heterocyclic compounds and their preparation and use |
US5852037A (en) * | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
EP0874828A4 (en) | 1995-12-06 | 1999-09-01 | Lilly Co Eli | Composition for treating pain |
AU7871498A (en) | 1996-12-20 | 1998-07-17 | Novo Nordisk A/S | A method of treating hypercholesterolemia and related disorders |
US7732163B2 (en) * | 1997-08-21 | 2010-06-08 | Board Of Trustees Of The University Of Arkansas | Extracellular serine protease |
US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
US8236500B2 (en) * | 1997-10-23 | 2012-08-07 | The United States Of America, As Represented By The Department Of Veterans Affairs | Promoter variants of the alpha-7 nicotinic acetylcholine receptor |
EP2295436A1 (en) * | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors |
US5952339A (en) * | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
AU2892999A (en) * | 1998-04-02 | 1999-10-25 | R.J. Reynolds Tobacco Company | Azatricyclo(3.3.1.1) decane derivatives and pharmaceutical compositions containing them |
US6057446A (en) * | 1998-04-02 | 2000-05-02 | Crooks; Peter Anthony | Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds |
US5986100A (en) * | 1998-04-02 | 1999-11-16 | Crooks; Peter Anthony | Pharmaceutical compositions and methods for use |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
WO1999062505A2 (en) | 1998-06-01 | 1999-12-09 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
DE69903961T2 (en) | 1998-08-18 | 2003-07-03 | Ucb Sa | MUSCARINAGONISTS AND ANTAGONISTS |
WO2000066586A1 (en) * | 1999-05-04 | 2000-11-09 | Neurosearch A/S | Heteroaryl diazabicycloalkanes, their preparation and use |
BR0011534A (en) | 1999-05-24 | 2002-02-26 | Targacept Inc | Substituted aryl alkylamines capable of activating nicotinic cholinergic receptors |
US20010031771A1 (en) * | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
WO2001040261A1 (en) | 1999-12-01 | 2001-06-07 | Ortho-Mcneil Pharmaceutical, Inc. | Method of diagnosing neurodegenerative disease |
DE60108639T2 (en) | 2000-07-04 | 2005-07-07 | Neurosearch A/S | ARYL AND HETEROARYLDIAZABICYCLOALCANES, THEIR PREPARATION AND USE |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
DE60220997T2 (en) | 2001-03-27 | 2008-03-13 | Eisai R&D Management Co., Ltd. | N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THIS AS AN ACTIVE SUBSTANCE |
FR2832713B1 (en) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | DERIVATIVES OF 4- (1,3,4-THIADIAZOL-2-YL) -1,4-DIAZABICYCLO [3.2.2] NONANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
JP2005538683A (en) * | 2001-12-14 | 2005-12-22 | ターガセプト,インコーポレイテッド | Methods and compositions for treatment of central nervous system disorders |
CA2480488A1 (en) | 2002-05-07 | 2003-11-20 | Neurosearch A/S | Novel diazabicyclic biaryl derivatives |
US7049374B2 (en) | 2002-07-18 | 2006-05-23 | Chevron U.S.A. Inc. | Heterodiamondoids |
AU2003250322B2 (en) | 2002-08-14 | 2010-01-21 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
US7030112B2 (en) * | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
ATE494903T1 (en) * | 2003-04-16 | 2011-01-15 | Merck Serono Sa | USE OF SLURP-1 TO TREAT DISEASES CAUSED BY ACETYLCHOLINE RECEPTOR DISRUPTIONS |
US7202363B2 (en) * | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
JP2005232071A (en) | 2004-02-19 | 2005-09-02 | Kanto Chem Co Inc | Pyrazole derivative |
JP2007535553A (en) * | 2004-04-29 | 2007-12-06 | アボット・ラボラトリーズ | Amino-tetrazole analogs and methods of use |
BRPI0510394A (en) | 2004-05-24 | 2007-11-13 | Amgen Inc | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
AR049401A1 (en) | 2004-06-18 | 2006-07-26 | Novartis Ag | AZA-BICICLONONANS |
FR2872165B1 (en) * | 2004-06-24 | 2006-09-22 | Sod Conseils Rech Applic | NEW PYRIMIDO-BENZIMIDAZOLE DERIVATIVES |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CA2574418A1 (en) | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
DK1781265T3 (en) * | 2004-08-25 | 2010-08-02 | Essentialis Inc | Pharmaceutical formulations of potassium ATP channel openers and applications thereof |
US7652010B2 (en) * | 2004-10-15 | 2010-01-26 | Neurosearch A/S | Azabicyclic aryl derivatives and their medical use |
JP2008517032A (en) | 2004-10-20 | 2008-05-22 | ノイロサーチ アクティーゼルスカブ | Novel diazabicyclic aryl derivatives and their pharmaceutical uses |
AU2004325725A1 (en) * | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
WO2007024391A2 (en) | 2005-07-22 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US9274099B2 (en) * | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US7897766B2 (en) * | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
AU2006323986A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
WO2008002594A2 (en) | 2006-06-27 | 2008-01-03 | Neuroprotection For Life Corp. | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors |
FR2905009A1 (en) | 2006-08-18 | 2008-02-22 | Servier Lab | METHOD OF SCREENING COMPOUNDS WITH ANTI-AMYLOID PROPERTIES |
US20100234349A1 (en) * | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
US20100152108A1 (en) * | 2006-10-27 | 2010-06-17 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
KR20090107567A (en) | 2007-02-09 | 2009-10-13 | 아스텔라스세이야쿠 가부시키가이샤 | Aza-bridged-ring compound |
WO2008106694A2 (en) * | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
EP2126131A2 (en) * | 2007-03-08 | 2009-12-02 | Genizon Biosciences, Inc. | Genemap of the human genes associated with schizophrenia |
JP5566698B2 (en) | 2007-03-23 | 2014-08-06 | アッヴィ・インコーポレイテッド | Azaadamantane esters and carbamate derivatives and methods for their use |
KR101122469B1 (en) | 2007-04-02 | 2012-07-12 | 파킨슨즈 인스티튜트 | Methods and compositions for reduction of side effects of therapeutic treatments |
WO2009017454A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
SA08290475B1 (en) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof |
US8697722B2 (en) * | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
WO2009058120A1 (en) | 2007-11-02 | 2009-05-07 | Sri International | Nicotinic acetylcholine receptor modulators |
WO2009066735A1 (en) | 2007-11-20 | 2009-05-28 | Nissan Chemical Industries, Ltd. | Method for producing 2-azaadamantane |
DE102007058504A1 (en) | 2007-12-05 | 2009-07-09 | Acino Ag | Transdermal therapeutic system containing a modulator of nicotinic acetylcholine receptors (nAChR) |
RU2481123C2 (en) * | 2008-02-13 | 2013-05-10 | Таргасепт, Инк. | Combination of alpha 7 nicotinic receptor agonists and antipsychotic agents |
US20090239901A1 (en) * | 2008-03-19 | 2009-09-24 | Merouane Bencherif | Method and compositions for treatment of cerebral malaria |
WO2009140201A1 (en) | 2008-05-12 | 2009-11-19 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
FR2931677B1 (en) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | ASSOCIATION OF A PARTIAL NICOTINIC RECEPTOR AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR, COMPOSITION CONTAINING THE SAME AND USE THEREOF IN THE TREATMENT OF COGNITIVE DISORDERS |
US20110097324A1 (en) * | 2008-06-13 | 2011-04-28 | Centre For Addiction And Mental Health | Compositions and methods for modulating nicotinic/nmda receptor function |
US8841329B2 (en) | 2008-09-11 | 2014-09-23 | Dignity Health | Nicotinic attenuation of CNS inflammation and autoimmunity |
EP2344636B1 (en) | 2008-10-09 | 2017-12-06 | Howard Hughes Medical Institute | Novel chimeric ligand-gated ion channels and methods of use thereof |
US20110262407A1 (en) | 2008-11-11 | 2011-10-27 | Targacept, Inc. | Treatment with alpha7 selective ligands |
US20110312894A1 (en) | 2009-01-28 | 2011-12-22 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
WO2011014817A1 (en) | 2009-07-31 | 2011-02-03 | Biocryst Pharmaceuticals, Inc. | Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors |
EP2467131A4 (en) | 2009-08-21 | 2014-02-19 | Univ Florida | Controlled-release formulations of anabaseine compounds and uses thereof |
US20120270844A1 (en) | 2009-10-09 | 2012-10-25 | Afraxis, Inc. | Methods for treating alzheimer's disease |
WO2011058582A1 (en) | 2009-11-16 | 2011-05-19 | Orchid Research Laboratories Ltd. | Histone deacetylase inhibitors for the treatment of fungal infections |
MX2013003344A (en) | 2010-09-23 | 2013-06-28 | Abbvie Inc | Monohydrate of an azaadamantane derivative. |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
-
2007
- 2007-11-05 US US11/935,157 patent/US8314119B2/en active Active
- 2007-11-06 AU AU2007316480A patent/AU2007316480B2/en not_active Ceased
- 2007-11-06 CN CN201310452391.6A patent/CN103554107B/en not_active Expired - Fee Related
- 2007-11-06 NZ NZ577474A patent/NZ577474A/en not_active IP Right Cessation
- 2007-11-06 RU RU2009121564/04A patent/RU2450002C2/en not_active IP Right Cessation
- 2007-11-06 EP EP07863920.0A patent/EP2099795B1/en active Active
- 2007-11-06 WO PCT/US2007/083687 patent/WO2008058096A2/en active Application Filing
- 2007-11-06 NZ NZ600178A patent/NZ600178A/en not_active IP Right Cessation
- 2007-11-06 BR BRPI0718028-4A patent/BRPI0718028A2/en not_active IP Right Cessation
- 2007-11-06 TW TW096141946A patent/TWI511729B/en not_active IP Right Cessation
- 2007-11-06 KR KR1020147024403A patent/KR20140116558A/en active IP Right Grant
- 2007-11-06 JP JP2009535497A patent/JP5275246B2/en not_active Expired - Fee Related
- 2007-11-06 PL PL07863920T patent/PL2099795T3/en unknown
- 2007-11-06 UA UAA200905813A patent/UA96961C2/en unknown
- 2007-11-06 MX MX2009004813A patent/MX2009004813A/en active IP Right Grant
- 2007-11-06 NZ NZ589813A patent/NZ589813A/en not_active IP Right Cessation
- 2007-11-06 MY MYPI20091774A patent/MY148253A/en unknown
- 2007-11-06 DK DK07863920.0T patent/DK2099795T3/en active
- 2007-11-06 MX MX2012005921A patent/MX340064B/en unknown
- 2007-11-06 PT PT78639200T patent/PT2099795E/en unknown
- 2007-11-06 KR KR1020157006394A patent/KR101654073B1/en active IP Right Grant
- 2007-11-06 KR KR1020147007297A patent/KR20140054300A/en active IP Right Grant
- 2007-11-06 SG SG2011082419A patent/SG176473A1/en unknown
- 2007-11-06 KR KR1020097011732A patent/KR101636439B1/en active IP Right Grant
- 2007-11-06 CA CA2668962A patent/CA2668962C/en not_active Expired - Fee Related
- 2007-11-06 NZ NZ618134A patent/NZ618134A/en not_active IP Right Cessation
- 2007-11-06 ES ES07863920.0T patent/ES2551117T3/en active Active
-
2009
- 2009-04-23 CR CR10743A patent/CR10743A/en unknown
- 2009-05-05 IL IL198587A patent/IL198587A/en not_active IP Right Cessation
- 2009-06-04 CO CO09057911A patent/CO6210720A2/en active IP Right Grant
- 2009-06-04 EC EC2009009388A patent/ECSP099388A/en unknown
- 2009-06-05 ZA ZA2009/03944A patent/ZA200903944B/en unknown
- 2009-06-08 NO NO20092181A patent/NO20092181L/en not_active Application Discontinuation
-
2010
- 2010-02-01 HK HK10101088.9A patent/HK1133645A1/en not_active IP Right Cessation
- 2010-11-29 ZA ZA2010/08549A patent/ZA201008549B/en unknown
-
2011
- 2011-09-29 DO DO2011000301A patent/DOP2011000301A/en unknown
-
2012
- 2012-01-27 RU RU2012102908/04A patent/RU2012102908A/en not_active Application Discontinuation
- 2012-10-16 US US13/653,192 patent/US8987453B2/en not_active Expired - Fee Related
-
2013
- 2013-01-22 JP JP2013008959A patent/JP5562449B2/en not_active Expired - Fee Related
- 2013-04-17 PH PH12013500745A patent/PH12013500745A1/en unknown
- 2013-05-13 ZA ZA2013/03483A patent/ZA201303483B/en unknown
- 2013-07-25 IL IL227668A patent/IL227668A/en not_active IP Right Cessation
-
2014
- 2014-06-09 JP JP2014118329A patent/JP5727651B2/en not_active Expired - Fee Related
- 2014-06-13 CR CR20140277A patent/CR20140277A/en unknown
-
2015
- 2015-01-20 DO DO2015000014A patent/DOP2015000014A/en unknown
- 2015-02-17 US US14/624,517 patent/US20150158867A1/en not_active Abandoned
- 2015-04-02 JP JP2015075967A patent/JP2015143260A/en active Pending
- 2015-10-20 DO DO2015000264A patent/DOP2015000264A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2015000014A (en) | DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME | |
CR11492A (en) | PEPTIDIL NITRILOS AND USE OF THE SAME AS INHIBITORS OF DIPEPTIDIL PEPTIDASA I | |
CL2016001287A1 (en) | Substituted benzamides and procedure for use | |
DOP2010000396A (en) | DERIVED FROM URACILO OR TIMINA FOR THE TREATMENT OF HEPATITIS C | |
CR11416A (en) | SOME DERIVATIVES OF 2-PIRAZINONA AND ITS USE AS INHIBITORS OF ELASTASA DE LOS NEUTROFILOS | |
AR062875A1 (en) | N-METHYLAMINOMETIL ISOINDOL COMPOUNDS AND COMPOSITIONS THAT INCLUDE THEM AND METHODS TO USE THEM | |
UY31806A (en) | TIAZOLE AND OXAZOLE COMPOUNDS OF BENZENE SULFONAMIDE | |
DOP2006000193A (en) | ISOINDOL-IMIDA COMPOUNDS AND COMPOSITIONS INCLUDING THEM AND METHODS FOR USE | |
ECSP10010722A (en) | ORGANIC COMPOUNDS | |
CR20110028A (en) | PIRIMIDINE DERIVATIVES AS CINASE INHIBITORS | |
CR11139A (en) | ANTI-NOTCH1 NRR ANTIBODIES AND THEIR METHODS OF USE | |
UY30977A1 (en) | DERIVATIVES OF ISOINDOLINAS 4 '-O-REPLACED. COMPOSITIONS THAT CONTAIN THEM AND METHODS FOR THEIR USES. | |
CR8986A (en) | ISOXAZOLS REPLACED AS FUNGICIDES | |
CR10156A (en) | METHODS TO PREPARE SUBSTITUTED AND INTERMEDIATE SULFONAMIDE ALCOHOLS OF THESE | |
CR9786A (en) | BENCIMIDAZOL-THIOPHEN COMPOUNDS | |
AR069531A1 (en) | INDOLINONE DERIVATIVES AND PROCEDURE FOR MANUFACTURING | |
GT200600117A (en) | NEW PHARMACEUTICAL COMPOUNDS | |
ECSP11011344A (en) | NEW ANTIBODIES ANTI-? 5? 1 AND ITS USES | |
CL2009001686A1 (en) | Process for preparing agomelatine; and the intermediate compounds considered. | |
CR20140135A (en) | NEW DERIVATIVES OF ARIL-QUINOLINA | |
ECSP088743A (en) | ANTIBODIES FOR EGFL7 AND METHODS FOR USE | |
UA106880C2 (en) | NEW HERBICIDES | |
BR112013018732A2 (en) | new aryl benzocycloalkyl amide derivatives | |
ECSP088700A (en) | 4-PHENYL-TIAZOL-5-CARBOXILIC ACIDS AND 4-PHENYL-TIAZOL-5-CARBOXILIC ACIDS AS INHIBITORS OF THE PLK1 | |
MX2015013365A (en) | Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors. |